EP Patent

EP4652986A3 — The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment

Assigned to Neurocrine Biosciences Inc · Expires 2026-01-07 · 0y expired

What this patent protects

Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.

USPTO Abstract

Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.

Drugs covered by this patent

Patent Metadata

Patent number
EP4652986A3
Jurisdiction
EP
Classification
—
Expires
2026-01-07
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.